|
Presenile dementia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An analysis by classification of dementia severity according to clinical dementia rating (CDR) showed that the EL levels were significantly higher in the CDR1 group (mild dementia), as compared to CDR0 (no dementia), CDR0.5 (very mild), and CDR2 (moderate) groups.
|
31216999 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stage of dementia (clinical dementia rating, CDR = 0, 1 and 2) showed that total and constructive praxis can be used to classify the stages of dementia (mild and moderate cases), i.e. constructive praxis classified 88% of the patients with mild dementia (P < 0.0001) while total praxis classified 56% with moderate dementia.
|
30570090 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The distinctive gait characteristics between the no-dementia and the imminent dementia groups in CDR 0.5 and CDR 1 remained the same as in the overall group.
|
31024419 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A hip fracture patient aged <80 years old, with an ASA I-II, with low dementia CDR index and on osteoporosis medication has a better chance of an improved outcome (winner patient).
|
31547719 |
2019 |
|
Presenile dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
More falls (3 in the placebo group vs 11 in the TPI-287 group) and a dose-related worsening of dementia symptoms (mean [SD] in the CDR plus NACC FTLD-SB [Clinical Dementia Rating scale sum of boxes with frontotemporal dementia measures], 0.5 [1.8] in the placebo group vs 0.7 [1.6] in the TPI-287 group; median difference, 1.5 [95% CI, 0-2.5]; P = .03) were seen in patients with 4RT.
|
31710340 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We compared 3 MCI subgroups who progressed to dementia (n=86), stabilized at MCI (n=384), or reverted to normal (n=252), to those who remained consistently normal (n=881), defining MCI as CDR = 0.5 and dementia as CDR≥1.
|
30444944 |
2019 |
|
Presenile dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In ADNP+ participants, greater WMH corresponded with increased odds for dementia (CDR≥1; p = 0.038).
|
29843242 |
2018 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
During stages of AD dementia (CDR1 and 2/3) peripheral myeloid cells increase their pro-inflammatory gene expression while at early stages of disease (prodromal AD-CDR0.5) pro-inflammatory gene expression is decreased.
|
30424785 |
2018 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The association between vaMTA and CDR-SB change was different in patients with MCI and Alzheimer's disease dementia.
|
28614836 |
2017 |
|
Presenile dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Detecting clinical change with the CDR-FTLD: differences between FTLD and AD dementia.
|
27464599 |
2017 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using the optimal cutoff value, the sensitivity/specificity for diagnosing CDR 0.5 and CDR 1 dementia were 87.5%/94.1% and 90.9%/93.3%, respectively.
|
26842588 |
2016 |
|
Presenile dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The baseline sample of 183 mutation carriers (MCs) and 117 noncarriers (NCs) was divided according to Clinical Dementia Rating (CDR) scale into preclinical (CDR 0; MCs: n = 107; NCs: n = 109), early symptomatic (CDR 0.5; MCs: n = 48; NCs: n = 8), and dementia stage (CDR ≥ 1; MCs: n = 28; NCs: n = 0).
|
25922840 |
2015 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of CCL-checkpoint and DNA damage response genes: MDM4, ATM and ATR was strongly upregulated and associated with progression of dementia (cognitive dementia rating, CDR), appearing as early as questionable or mild dementia (CDRs 0.5-1).
|
23861893 |
2013 |